Abstract 124P
Background
BRAF V600E is identified approximately 5-9% of colorectal cancer (CRC) patients. Non-V600E BRAF mutation is characterized a rare molecular subtype. The clinical characteristics and prognostic impact of non-V600 BRAF mutants are not well defined.
Methods
We recruited 829 patients with CRC from our institution. Tissue samples were molecularly tested. Clinical data was retrospectively reviewed and analyzed using Chi-square and t-test. Overall survival (OS) was compared by log-rank test.
Results
All BRAF mutation was detected in 50 (6%) patients including 24 (3%) patients with non-V600 mutations. Patient characteristics and BRAF testing technique were not significantly different based on BRAF status and it was comparable between BRAF V600E and non-V600 groups. There were significantly more ALL RAS and PIK3CA mutations in non-V600 mutant patients. Patients with non-V600 mutation had median OS of 82 months which was longer than BRAF WT, 66 months, and 31 months of BRAF V600E group, respectively (P=0.067). OS according to treatment with anti-EGFR in metastatic CRC patients was not significantly different in both V600E and non-V600 BRAF mutant groups. Table: 124P
| BRAF-MT (n=50) | |||||||
| BRAF-WT (n=779) | BRAF-MT (n=50) | p-value | V600 (n=26) | non-V600 (n=24) | p-value | ||
| Age | 63 (18 - 93) | 65 (19-85) | 66 (19 - 85) | 65 (24 - 83) | |||
| Sex | |||||||
| Male | 471 (60) | 32 (64) | 0.62 | 15 (58) | 17 (71) | 0.333 | |
| Female | 308 (40) | 18 (36) | 11 (42) | 7 (29) | |||
| Sidedness | |||||||
| Left | 591 (76) | 33 (66) | 0.289 | 12 (70) | 15 (62) | 0.878 | |
| Right | 168 (22) | 15 (30) | 7 (27) | 8 (33) | |||
| non-specify | 20 (3) | 2 (4) | 1 (4) | 1 (4) | |||
| Technique | |||||||
| NGS | 547 (70) | 38 (76) | 0.466 | 18 (69) | 20 (83) | 0.26 | |
| Pyrosequencing | 84 (11) | 6 (12) | 5 (19) | 1 (4) | |||
| PCR | 148 (19) | 6 (12) | 3 (12) | 2 (12) | |||
| All RAS mutation | 418 (54) | 8 (16) | <0.001 | 0 | 8 (33) | 0.001 | |
| PIK3CA mutation | 94 (12) | 9 (18) | 0.218 | 1 (4) | 8 (33) | 0.009 | |
| Recur/Met | (n=575) | (n=35) | (n=19) | (n=16) | |||
| Anti-VEGF | 105 (18) | 7 (20) | 0.796 | 2 (11) | 5 (31) | 0.207 | |
| Anti-EGFR | 162 (28) | 6 (17) | 0.156 | 3 (16) | 3 (19) | 1 |
Conclusions
Non-V600 BRAF mutation may indicate better prognosis. The difference in treatment effect was not demonstrated in patients with BRAF mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of medicine Ramathibodi Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract